Abstract:A 37-year-old woman was evaluated at our hospital for a treatment-resistant proctosigmoiditis. Fifteen years previously, ulcerative colitis was suspected and she was cured by steroid therapy. Colonoscopy revealed multiple sessile polyps covered with white exudate from the rectum to the sigmoid colon. Histopathological examination revealed a mucosal surface cover of granulation tissue. Based on these findings, cap polyposis was diagnosed. She underwent Helicobacter pylori eradication therapy, and at 1 month aft… Show more
“…Some authors hypothesized that its e cacy may be due to other bacteria reacting to the H. pylori eradication therapy or to a systemic immune response caused by sustained H. pylori infection. e intervals from eradication therapy to symptom relief and polyp disappearance were 3 days-1 month and 2-14 months, respectively [10][11][12][13][14].…”
We report the case of a 58-year-old woman who was referred to our hospital due to frequent bloody mucus diarrhea. She was diagnosed with cap polyposis based on typical endoscopic and histological findings. Colonoscopy revealed multiple, reddish, mucus-capped polypoid lesions from the rectum to the sigmoid colon. A pathological examination revealed that the polyps were covered by erosive and inflamed granulation tissue with decreased crypt cells. Laboratory data indicated positive values for Helicobacter pylori immunoglobulin G antibody and hypoproteinemia. Metronidazole, H. pylori eradication, and levofloxacin therapies were not effective; however, the subsequent administration of betamethasone enema dramatically improved the clinical symptoms and endoscopic findings. The hypoproteinemia was normalized after the therapy. The dose of the betamethasone enema was tapered gradually, and no recurrence was observed 6 months after discontinuation of the treatment. This case suggests that betamethasone enema may be considered as the second treatment choice for cap polyposis patients after H. pylori eradication, metronidazole or levofloxacin therapy.
“…Some authors hypothesized that its e cacy may be due to other bacteria reacting to the H. pylori eradication therapy or to a systemic immune response caused by sustained H. pylori infection. e intervals from eradication therapy to symptom relief and polyp disappearance were 3 days-1 month and 2-14 months, respectively [10][11][12][13][14].…”
We report the case of a 58-year-old woman who was referred to our hospital due to frequent bloody mucus diarrhea. She was diagnosed with cap polyposis based on typical endoscopic and histological findings. Colonoscopy revealed multiple, reddish, mucus-capped polypoid lesions from the rectum to the sigmoid colon. A pathological examination revealed that the polyps were covered by erosive and inflamed granulation tissue with decreased crypt cells. Laboratory data indicated positive values for Helicobacter pylori immunoglobulin G antibody and hypoproteinemia. Metronidazole, H. pylori eradication, and levofloxacin therapies were not effective; however, the subsequent administration of betamethasone enema dramatically improved the clinical symptoms and endoscopic findings. The hypoproteinemia was normalized after the therapy. The dose of the betamethasone enema was tapered gradually, and no recurrence was observed 6 months after discontinuation of the treatment. This case suggests that betamethasone enema may be considered as the second treatment choice for cap polyposis patients after H. pylori eradication, metronidazole or levofloxacin therapy.
“…Géhénot et al[ 19 ] suggested the possibility of bacterial infection, reporting on a cap polyposis patient who had no evidence of colonic dysmotility and who was successfully treated with metronidazole. Of the myriad gut microbiota, although H. pylori is not detected in mucosa obtained from cap polyposis lesions[ 10 ], most cases of cap polyposis with H. pylori infection have resolved after H. pylori eradication therapy[ 10 , 11 , 15 , 16 , 18 ]. H. pylori infection is well-known to cause not only gastroduodenal diseases, but also diseases such as idiopathic thrombocytopenic purpura and chronic idiopathic urticaria[ 20 , 21 ].…”
Section: Discussionmentioning
confidence: 99%
“…The patient had no evidence of H. pylori infection by urea breath test, anti- H. pylori antibody, or endoscopic findings ( i.e ., gastric mucosal atrophy or diffuse redness of gastric mucosa). However, according to previous evidence that H. pylori eradication therapy was effective for patients with cap polyposis[ 10 , 11 , 15 , 16 ], H. pylori eradication therapy with vonoprazan 20 mg, amoxicillin 750 mg and clarithromycin 200 mg twice daily for 7 d was initiated. Abdominal symptoms ( i.e ., hematochezia and tenesmus), bowel habits, and endoscopic findings did not improve over the six months after therapy.…”
Section: Case Reportmentioning
confidence: 99%
“…Some cases have been treated successfully by the avoidance of straining at defecation[ 8 ], antimicrobial agents ( i.e ., metronidazole)[ 9 ], steroids[ 2 ], immunomodulators ( i.e ., infliximab)[ 12 ], endoscopic therapy[ 13 , 14 ] and surgical resection[ 5 - 7 ]. Recently, the efficacy of Helicobacter pylori ( H. pylori ) eradication therapy for H. pylori- positive patients with cap polyposis has been reported[ 10 , 11 , 15 , 16 ], and in 2016 the Japanese Society for Helicobacter Research added cap polyposis as a possible H. pylori -associated disease in its treatment guidelines. However, no treatments for H. pylori -negative cap polyposis or H. pylori -positive cases refractory to eradication therapy have yet been established.…”
Cap polyposis is a rare intestinal disorder. Characteristic endoscopic findings are multiple inflammatory polypoid lesions covered by caps of fibrous purulent exudate. Although a specific treatment has not been established, some studies have suggested that eradication therapy for Helicobacter pylori (H. pylori) is effective. We report a case of a 20-year-old man with cap polyposis presenting with hematochezia. Colonoscopy showed the erythematous polyps with white caps from the sigmoid colon to rectum. Histopathological findings revealed elongated, tortuous, branched crypts lined by hyperplastic epithelium with a mild degree of fibromusculosis in the lamina propria. Although H. pylori eradication was instituted, there was no improvement over six months. We then performed en bloc excision of the polyps by endoscopic submucosal dissection (ESD), which resulted in complete resolution of symptoms. ESD may be a treatment option for cap polyposis refractory to conservative treatments. We review the literature concerning treatment for cap polyposis and clinical outcomes.
“…Conservative treatment modalities like avoidance of straining at defecation, use of metronidazole, infliximab, Helicobacter pylori eradication therapy and endoscopic polypectomy have been shown to be beneficial in some cases. [1314] Surgical resection should be reserved for patients with recurrence or for those who don’t respond to conservative therapy. To conclude, rectal CP should be considered in the differential diagnosis of patients presenting clinically with intermittent rectal bleeding and rectal polyposis on endoscopic examination.…”
Cap polyposis (CP) is an under recognized form of non-neoplastic colonic polyps, characterised by the presence of inflammatory polyps with a distinct “cap” of granulation tissue. CP is often seen masquerading as chronic inflammatory bowel disease. The most common symptoms are mucoid diarrhoea, bloody stools, abdominal pain, and tenesmus. In this case report, we present a patient who was diagnosed with CP during the investigation of unexplained chronic long standing anemia secondary to intermittent rectal bleeding. CP, although rare, should be considered in the differential diagnosis of patients presenting with intermittent rectal bleeding and mucoid diarrhoea.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.